The 55th International hospital and medical equipment exhibition, MEDICA 2023, was held in Düsseldorf, Germany from November 13th to 16th, 2023. Recognized as one of the world's largest medical B2B trade fairs, MEDICA has always been regarded as a barometer for the development of the medical industry. This year, it attracted an impressive number of over 5,300 exhibitors from 68 countries and welcomed over 83,000 professional visitors from around the globe. Hybribio was invited to this grand medical festival, joining numerous Chinese enterprises to showcase China’s wisdom and innovation to the world.

Innovation from China

Located at Hall 3 of Messe Düsseldorf, Hybribio presented a series of nucleic acid molecular diagnostic solutions including cervical cancer HPV, reproductive tract infection, genetic diseases, cancer methylation, etc. In addition, Hybribio's cutting-edge fully automated sample preparation liquid handling system HB-IEX96A made its first formal appearance in European market.

As the leading HPV test producer in China, Hybribio has set high standards in the industry. All of Hybribio HPV nucleic acid diagnostic kits have obtained EU CE certification, a testament to product quality and reliability. Moreover, these kits have been accredited with 100% concordance by WHO HPV EQA for 7 consecutive times from 2011 to 2022. This accreditation provides a reliable guarantee for high-quality cervical cancer diagnostic tests, further demonstrating Hybribio’s commitment to advancing healthcare and improving patient outcomes.

Wisdom from China

Hybribio, a pioneer in cervical cancer screening in China, is entering a new phase of growth. Committed to the elimination of cervical cancer, Hybribio is eager to share its extensive expertise in cervical cancer prevention and control with the world.

At the MEDICA venue, by showcasing precise testing reagents, intelligent fully automated instruments, and digital intelligent management systems, Hybribio’s booth drew a crowd of interested visitors to stop by, engage in deep discussions and learn more about Hybribio’s work. They were particularly impressed with Hybribio’s dedication to HPV testing for cervical cancer and the appeal of “Hybribio Medtech”. Many expressed their willingness to introduce Hybribio’s diagnostic solutions to their respective countries to benefit their local communities.

Hybribio has been at the forefront of the fight against cervical cancer, responding to the WHO’s global strategy towards the elimination of cervical cancer by 2030. The company has been tirelessly promoting advanced HPV diagnostic methods and the prevention and treatment of cervical cancer. Hybribio offers a comprehensive solution for the early prevention and diagnosis of cervical cancer, as well as for its precise triage and therapeutic management. As of June 2023, Hybribio has provided over 62 million HPV tests for women in China, forming a robust shield for women’s health.

The year 2023 marks the third year of the global campaign to accelerate the elimination of cervical cancer. In this significant year, Hybribio’s 14 High-risk HPV with 16/18 Genotyping Real-time PCR kit has achieved a milestone. It successfully obtained the first NMPA approval for cervical cancer primary screening in June, further solidifying Hybribio’s commitment to this crucial cause.

In addition, Hybribio’s 14 High-risk HPV E6/E7 mRNA Real-time PCR kit has received approval from the NMPA. This kit offers a more accurate triage management for the screening-positive population, further enhancing Hybribio’s product portfolio. With its comprehensive screening and diagnostic pathway, Hybribio showcases its extensive experience in cervical cancer screening and diagnostics to the world.

The journey towards accelerating the elimination of cervical cancer is indeed long and fraught with challenges. However, Hybribio remains steadfast in its commitment to safeguarding women’s health, and continues to collaborate with various counterparts to realize the goal of globally eliminating cervical cancer.